Please enable JavaScript.  This webapp requires JavaScript to work at its best.

AE Management Guide

The guide supports healthcare professionals to manage adverse events (AE) that may result from the use of LENVIMA® (lenvatinib) in their patients with Endometrial Cancer.

It provides guidance on how to monitor and manage most common AEs based on the Summary of Product Characteristics.

Supporting documentation:

LENVIMA® 4 mg hard capsules Summary of Product Characteristics
LENVIMA® 10 mg hard capsules Summary of Product Characteristics

 

GB-KLE-00104 Date of preparation April 2023